MX346312B - Tratamientos oftalmicos. - Google Patents
Tratamientos oftalmicos.Info
- Publication number
- MX346312B MX346312B MX2013011314A MX2013011314A MX346312B MX 346312 B MX346312 B MX 346312B MX 2013011314 A MX2013011314 A MX 2013011314A MX 2013011314 A MX2013011314 A MX 2013011314A MX 346312 B MX346312 B MX 346312B
- Authority
- MX
- Mexico
- Prior art keywords
- eye
- compositions
- pharmaceuticals
- tramadol
- analgesic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La presente invención se relaciona con composiciones acuosas apropiadas para la administración tópica al ojo humano o animal, que contiene por lo menos un lubricante oftálmico polimérico, soluble en agua, tal como hialuronato, gel de carbómero o hipromelosa, junto con un analgésico soluble en agua. El analgésico puede ser un opioide, particularmente un opioide que tiene una afinidad para los receptores de 5-HT, tal como tramadol. Los niveles de tramadol típicos estarían en el intervalo de 0.5% a 1.0 p/v. Por ejemplo, las composiciones acuosas pueden usarse como lágrimas artificiales, y como lubricantes oftálmicos generales para el tratamiento de las afecciones, tales como ojo seco o blefaritis. Las composiciones adicionales combinan los agentes oftalmológicamente activos, tales como farmacéuticos, con opioides, en particular, tal como tramadol. Estas composiciones pueden usarse para tratar el ojo, mientras que reducen el dolor o el malestar que sería producido normalmente por la administración de estos farmacéuticos particulares al ojo, y aumentar la eficacia de los farmacéuticos. También se describen composiciones, que contienen opioides con actividad del receptor de 5-HT, los cuales son de uso general para aliviar el dolor en, o alrededor del ojo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1105732.0A GB201105732D0 (en) | 2011-04-05 | 2011-04-05 | Ophthalmic lubricants |
GBGB1105731.2A GB201105731D0 (en) | 2011-04-05 | 2011-04-05 | Topical analgesics |
PCT/GB2012/000330 WO2012136969A2 (en) | 2011-04-05 | 2012-04-05 | Ophthalmic treatments |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013011314A MX2013011314A (es) | 2014-03-27 |
MX346312B true MX346312B (es) | 2017-03-15 |
Family
ID=46086008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013011314A MX346312B (es) | 2011-04-05 | 2012-04-05 | Tratamientos oftalmicos. |
Country Status (12)
Country | Link |
---|---|
US (2) | US20140088199A1 (es) |
EP (2) | EP2694048B1 (es) |
JP (2) | JP6148664B2 (es) |
KR (2) | KR102165246B1 (es) |
CN (2) | CN107982211A (es) |
BR (1) | BR112013025493A2 (es) |
CA (1) | CA2869280C (es) |
ES (1) | ES2836808T3 (es) |
HK (1) | HK1254720A1 (es) |
MA (1) | MA35070B1 (es) |
MX (1) | MX346312B (es) |
WO (1) | WO2012136969A2 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2694048B1 (en) * | 2011-04-05 | 2020-10-07 | Optosolve Research & Development Ltd | Ophthalmic treatments |
GB201217522D0 (en) * | 2012-10-01 | 2012-11-14 | Sharma Anant | ophthalmic therapy |
CA2909117A1 (en) * | 2013-04-09 | 2014-10-16 | Cresset Biomolecular Discovery Ltd | The treatment of inflammatory disorders |
ES2540151B1 (es) * | 2013-10-11 | 2016-02-29 | Farmalider S.A. | Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico |
RU2549472C1 (ru) * | 2013-12-26 | 2015-04-27 | Илья Александрович Марков | Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз |
EP3091985B1 (en) * | 2014-01-10 | 2024-05-08 | Manistee Therapeutics, Inc. | Prostanglandins for topical use in the treatment of migraines. |
US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
MX2017010544A (es) * | 2015-02-24 | 2018-06-18 | Univ Illinois | Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo. |
US9877964B2 (en) | 2015-02-24 | 2018-01-30 | Ocugen, Inc. | Methods and compositions for treating dry eye disease and other eye disorders |
EP3302426A4 (en) | 2015-05-29 | 2018-12-05 | Sydnexis, Inc. | D2o stabilized pharmaceutical formulations |
ES2604816B1 (es) | 2015-09-09 | 2018-01-29 | Farmalider, S.A. | Composición farmacéutica de tramadol para uso oftálmico |
US20180344676A1 (en) * | 2015-09-30 | 2018-12-06 | George Edward Hoag | Topical analgesic pain relief formulations, manufacture and methods of use thereof |
CN105232449B (zh) * | 2015-10-30 | 2019-04-09 | 上海昊海生物科技股份有限公司 | 盐酸莫西沙星透明质酸钠缓释纳米凝胶及其制备方法 |
CN110114119B (zh) | 2016-10-12 | 2022-05-31 | Ps治疗有限公司 | 人工泪液、隐形眼镜和药物载体组合物及其使用方法 |
EP3624773A4 (en) | 2017-05-19 | 2021-04-07 | Ocugen, Inc. | OPHTHALMIC COMPOSITIONS AND METHOD OF USE |
US20180353504A1 (en) * | 2017-06-08 | 2018-12-13 | Eye Therapies, Llc | Low-dose brimonidine combinations and uses thereof |
MX2018003456A (es) | 2017-12-21 | 2019-09-06 | Gruenenthal Gmbh | Combinacion farmaceutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor. |
TW201945011A (zh) * | 2018-03-13 | 2019-12-01 | 日商參天製藥股份有限公司 | 點眼型洗眼藥用組合物 |
AU2020321466A1 (en) | 2019-07-26 | 2022-02-17 | Proqr Therapeutics Ii B.V. | Ophthalmic compositions comprising viscosifying polymers and nucleic acids |
US11504269B2 (en) | 2019-11-19 | 2022-11-22 | Jennifer L. Fabian | Therapeutic bra |
CN112007028A (zh) * | 2020-09-03 | 2020-12-01 | 北京博纳致恒科技有限责任公司 | 一种复合睫状肌松弛剂的人工泪液及用途 |
WO2022183051A1 (en) * | 2021-02-26 | 2022-09-01 | Vyluma Inc. | Methods and formulations for topical administration of gabapentinoids |
WO2023285878A1 (en) * | 2021-07-13 | 2023-01-19 | Aviation-Ophthalmology | Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions |
WO2024010039A1 (ja) * | 2022-07-06 | 2024-01-11 | ロート製薬株式会社 | 眼科組成物 |
WO2024010040A1 (ja) * | 2022-07-06 | 2024-01-11 | ロート製薬株式会社 | 眼科組成物 |
WO2024010044A1 (ja) * | 2022-07-06 | 2024-01-11 | ロート製薬株式会社 | 眼科組成物 |
WO2024010045A1 (ja) * | 2022-07-06 | 2024-01-11 | 学校法人金沢医科大学 | 疼痛抑制剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6384043B1 (en) | 1993-02-01 | 2002-05-07 | Gholam A. Peyman | Methods of alleviating pain sensations of the denuded eye with opioid analgesics |
US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
EP0946157B1 (en) * | 1996-12-16 | 2002-03-13 | Alcon Laboratories, Inc. | The topical use of kappa opioid agonists to treat ocular pain |
US6174878B1 (en) * | 1999-08-31 | 2001-01-16 | Alcon Laboratories, Inc. | Topical use of kappa opioid agonists to treat otic pain |
JP2004143157A (ja) * | 2002-10-01 | 2004-05-20 | Taisho Pharmaceut Co Ltd | 点眼剤 |
US20060172972A1 (en) * | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
EP1768650B1 (en) * | 2004-06-04 | 2008-07-16 | Camurus Ab | Liquid depot formulations |
EP1611877A1 (en) * | 2004-06-28 | 2006-01-04 | Universidade de Coimbra | Method for preparing sustained-release therapeutic ophthalmic articles using compressed fluids for impregnation of drugs |
WO2007057508A2 (en) * | 2005-11-18 | 2007-05-24 | Orion Corporation | Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol |
EP1981491A4 (en) * | 2006-01-25 | 2009-09-23 | Aciex Inc | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DROUGHT |
EP2160182A1 (en) * | 2007-05-24 | 2010-03-10 | Aciex Therapeutics, Inc. | Formulations and methods for treating dry eye |
EP2311446A1 (en) * | 2009-10-16 | 2011-04-20 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising Tramadol and Celecoxib in the treatment of pain |
EP2694048B1 (en) * | 2011-04-05 | 2020-10-07 | Optosolve Research & Development Ltd | Ophthalmic treatments |
-
2012
- 2012-04-05 EP EP12721571.3A patent/EP2694048B1/en active Active
- 2012-04-05 ES ES12721571T patent/ES2836808T3/es active Active
- 2012-04-05 MA MA36378A patent/MA35070B1/fr unknown
- 2012-04-05 WO PCT/GB2012/000330 patent/WO2012136969A2/en active Application Filing
- 2012-04-05 KR KR1020187038197A patent/KR102165246B1/ko active IP Right Grant
- 2012-04-05 JP JP2014503208A patent/JP6148664B2/ja active Active
- 2012-04-05 MX MX2013011314A patent/MX346312B/es active IP Right Grant
- 2012-04-05 CN CN201711200533.4A patent/CN107982211A/zh active Pending
- 2012-04-05 CN CN201280025096.6A patent/CN103687594A/zh active Pending
- 2012-04-05 BR BR112013025493A patent/BR112013025493A2/pt not_active Application Discontinuation
- 2012-04-05 EP EP20200285.3A patent/EP3799866A1/en active Pending
- 2012-04-05 US US14/009,397 patent/US20140088199A1/en not_active Abandoned
- 2012-04-05 CA CA2869280A patent/CA2869280C/en active Active
- 2012-04-05 KR KR1020137029016A patent/KR20140145948A/ko active Application Filing
-
2016
- 2016-03-21 US US15/076,098 patent/US9913813B2/en active Active
-
2017
- 2017-03-07 JP JP2017043172A patent/JP6419876B2/ja active Active
-
2018
- 2018-10-26 HK HK18113731.7A patent/HK1254720A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3799866A1 (en) | 2021-04-07 |
CN107982211A (zh) | 2018-05-04 |
EP2694048A2 (en) | 2014-02-12 |
ES2836808T3 (es) | 2021-06-28 |
EP2694048B1 (en) | 2020-10-07 |
BR112013025493A2 (pt) | 2017-03-01 |
HK1254720A1 (zh) | 2019-07-26 |
JP2017141243A (ja) | 2017-08-17 |
JP6419876B2 (ja) | 2018-11-07 |
KR20140145948A (ko) | 2014-12-24 |
KR102165246B1 (ko) | 2020-10-13 |
US9913813B2 (en) | 2018-03-13 |
US20160199320A1 (en) | 2016-07-14 |
CA2869280C (en) | 2020-03-10 |
CN103687594A (zh) | 2014-03-26 |
JP2014513073A (ja) | 2014-05-29 |
MX2013011314A (es) | 2014-03-27 |
MA35070B1 (fr) | 2014-04-03 |
US20140088199A1 (en) | 2014-03-27 |
WO2012136969A3 (en) | 2013-01-03 |
KR20190004815A (ko) | 2019-01-14 |
JP6148664B2 (ja) | 2017-06-14 |
CA2869280A1 (en) | 2012-10-11 |
WO2012136969A2 (en) | 2012-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX346312B (es) | Tratamientos oftalmicos. | |
MX2020005217A (es) | Composicion oftalmica y dispositivo de administracion de la misma. | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
MX2010003774A (es) | Formulaciones oftalmicas acuosas. | |
MX2021000376A (es) | Composiciones tópicas para el alivio del dolor. | |
BR112015001158A2 (pt) | formulação oftálmica e respectivo uso e método para melhorar, reduzir ou tratar presbiopia | |
WO2011053801A3 (en) | Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye | |
WO2012063237A3 (en) | Buffered ophthalmic compositions and methods of use thereof | |
MX2020010907A (es) | Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central. | |
BRPI0821683B8 (pt) | uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz | |
RU2013141845A (ru) | Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа | |
WO2009090624A3 (es) | Gel de quitosano para aplicaciones dermatológicas, proceso de obtención y uso del mismo | |
MX345042B (es) | Composiciones y métodos para tratamiento no quirúrgico de ptosis. | |
MY147864A (en) | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | |
MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
NZ766141A (en) | Isoxazoline parasiticide formulations and methods for treating blepharitis | |
MX342930B (es) | Composicion reticuladora mejorada, suministrada por iontoforesis, util para el tratamiento de queratocono. | |
MD20140004A2 (en) | Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia | |
WO2015063613A3 (en) | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: OPTOSOLVE RESEARCH & DEVELOPMENT LIMITED |
|
FG | Grant or registration |